12 completed, 3 unknown, 1 not yet recruiting, 1 recruiting. 18 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Completed 12, Unknown 3, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 7 | Completed 3, Not yet recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1 |
Follow AIDS: new trials by email Literature Review of AIDS trials Research Report on AIDS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS Sintilimab - HIV, AIDS | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Public Health Clinical Center | 50 | 2026-05-01 | 2026-05-12 |
| Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage mesenchymal stem cell, saline - AIDS | Phase 1 / Phase 2 | Recruiting | Cell Energy Life Sciences Group Co. LTD | 150 | 2023-12-10 | 2025-08-12 |
| Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease N-803 - Hiv, HIV Infections | Phase 1 | Completed | University of Minnesota | 10 | 2021-04-01 | 2024-04-02 |
| N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV N-803 and bNAbs, haNK™ Cells - Hiv, HIV/AIDS | Phase 1 / Phase 2 | Withdrawn | University of Minnesota | 2020-01-01 | 2020-10-22 | |
| An Efficacy and Safety Study of shRNA-modified CD34+ Cells in HIV-infected Patients. shRNA-modified CD34+ cells, Low dose busulfan preconditioning, Busulfan preconditioning - HIV Infections, AIDS | Phase 1 | Unknown | Shanghai Public Health Clinical Center | 6 | 2018-02-27 | 2020-02-19 |
| Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults Ad35-GRIN, MVA.HIVconsv, pSG2.HIVconsv DNA - AIDS | Phase 1 / Phase 2 | Completed | University of Oxford | 72 | 2014-03-01 | 2016-05-30 |
| Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein Tat Oyi - AIDS | Phase 1 / Phase 2 | Unknown | BIOSANTECH | 50 | 2013-02-01 | 2016-02-10 |
| Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations Extended-Release Naltrexone - HIV, AIDS | Phase 1 / Phase 2 | Completed | Yale University | 151 | 2011-03-01 | 2020-03-19 |
| Bioequivalence Study of Pediatric Formulations to Treat HIV Infection Epivir®, Retrovir® and Viramune®, Lamivudine, Zidovudine and nevirapine, Lamivudine, zidovudine, nevirapine - HIV, AIDS | Phase 1 | Unknown | Elim Pediatric Pharmaceuticals Inc. | 24 | 2010-10-01 | 2011-11-10 |
| Study Targeting Affect Regulation Resilient Affective Processing Therapy (RAPT) - HIV, AIDS | Phase 1 / Phase 2 | Completed | University of California, San Francisco | 56 | 2010-09-01 | 2014-10-27 |
| Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine Blood collection, GSK HIV vaccine 732462 - AIDS | Phase 1 | Completed | GlaxoSmithKline | 190 | 2010-03-22 | 2018-03-02 |
| Safety of the HIV Vaccine 732462 in HIV Infected Subjects Aged 18 to 55 Years Old HIV Vaccine 732462, Placebo vaccine - AIDS | Phase 1 | Completed | GlaxoSmithKline | 41 | 2009-02-03 | 2018-06-18 |
| VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy Volunteer Efavirenz; Tenofovir disoproxil fumarate; Telaprevir - Hepatitis C, HCV | Phase 1 | Completed | Tibotec BVBA | 20 | 2009-02-01 | 2010-12-17 |
| TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects. TMC125 - HIV, AIDS | Phase 1 | Completed | Tibotec Pharmaceuticals, Ireland | 18 | 2008-09-01 | 2011-06-09 |
| TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers. Darunavir - HIV, AIDS | Phase 1 | Completed | Tibotec Pharmaceuticals, Ireland | 21 | 2008-08-01 | 2011-06-09 |
| TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women. TMC278 - HIV, AIDS | Phase 1 | Completed | Tibotec Pharmaceuticals, Ireland | 18 | 2008-07-01 | 2010-04-28 |
| TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function. TMC278 - HIV, AIDS | Phase 1 | Completed | Tibotec Pharmaceuticals, Ireland | 32 | 2008-06-01 | 2010-04-28 |
| Study of Enfuvirtide in HIV-Positive Subjects Fuzeon - HIV Infections, AIDS | Phase 1 | Completed | Trimeris | 26 | 2005-06-24 |
Acquired Immunodeficiency Syndrome (18) · HIV Infections (7) · Substance-Related Disorders (2) · Hepatitis C (1) · Infections (1) · Mycoses (1) · Opioid-Related Disorders (1) · Opportunistic Infections (1) · Wounds and Injuries (1)
Blood-Borne Infections (18) · Communicable Diseases (18) · Genital Diseases (18) · Immune System Diseases (18) · Immunologic Deficiency Syndromes (18) · Lentivirus Infections (18) · RNA Virus Infections (18) · Retroviridae Infections (18) · Sexually Transmitted Diseases (18) · Sexually Transmitted Diseases, Viral (18) · Slow Virus Diseases (18) · Urogenital Diseases (18) · Virus Diseases (18) · Infections (17) · HIV Infections (11)
ALT-803 (2) · Rilpivirine (2) · Blood Specimen Collection (1) · Broadly Neutralizing Antibodies (1) · Busulfan (1) · Darunavir (1) · Enfuvirtide (1) · Lamivudine (1) · Naltrexone (1) · Nevirapine (1) · Sodium Chloride (1) · Tenofovir (1) · Zidovudine (1) · efavirenz (1) · etravirine (1)
Tibotec Pharmaceuticals, Ireland (4) · GlaxoSmithKline (2) · Shanghai Public Health Clinical Center (2) · University of Minnesota (2) · BIOSANTECH (1) · Cell Energy Life Sciences Group Co. LTD (1) · Elim Pediatric Pharmaceuticals Inc. (1) · Tibotec BVBA (1) · Trimeris (1) · University of California, San Francisco (1) · University of Oxford (1) · Yale University (1)
United States (6) · China (3) · France (2) · Germany (2) · Kenya (1) · Nigeria (1) · Spain (1)
Timothy Schacker, MD (2) · Adam Carrico, PhD (1) · Daniel A Gbadero, MD (1) · Frederick L Altice (1) · Fu-Sheng Wang, Doctor (1) · Hongzhou Lu, Ph.D (1) · Isabelle Ravaux, MD (1) · Moji C Adeyeye, Ph.D (1) · Sandra A Springer, MD (1) · Walter Jaoko (1)
PMID 23400742, PMID 24144472, PMID 24161160, PMID 24674234, PMID 26560326, PMID 29373393, PMID 29606517, PMID 40342086, PMID 40471871
2009 (1), 5UM1AI126611 (1), K02DA032322 (1)